chartexchange

RGC
Regencell Bioscience Holdings Limited
stockNASDAQ

Market OpenOct 29, 2026 9:42:03 AM EDT
7.13USD-1.926%(-0.14)14,623
6.1100Bid8.7800Ask2.6700Spread
Loading…
Loading…
Healthcare
Drug Manufacturers-Specialty & Generic
HQ
Causeway Bay, TN, Hong Kong
26,000
Previous Close
$7.30
Beta
1.51
52-Week High
$69.00 2026-01-08
52-Week Low
$4.51 2026-07-17
SMA 50
$6.78
SMA 200
$17.42
Avg. Vol 10D
571,125
Avg. Vol 30D
317,102
Avg. Vol 90D
322,462
Relative Vol
0.04
495.88M
17.30M
149.7100%
6,169
Jun 16, 2025 · 38-for-1
RGC Profile

we are an early-stage bioscience company that focuses on research, development and commercialization of tcm for the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder ("adhd"), autism spectrum disorder ("asd") in infectious diseases such as covid-19. our goal is to improve the lives of adhd, asd and covid patients, their families and caregivers and become a market leader for the best tcm treatment globally.

RGC Performance
PeriodPriceDateChangeBeta
1W9.812026-10-22-26.73%16.409
1M6.202026-09-29+15.94%4.524
3M5.652026-07-29+27.23%2.796
6M28.952026-04-29-75.17%1.219
1Y16.612025-10-29-56.72%1.511
2Y0.192024-10-29+3661.49%—
5Y0.352021-10-29+1934.01%0.137
RGC Stock Summary

Regencell Bioscience Holdings Limited (NASDAQ:RGC) stock price today is $7.19, and today's volume is 12,112. RGC is down 1.125% today. The 30 day average volume is 317,102. RGC market cap is $3.56B with 495.88M shares outstanding.